Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism

This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel therapies for heart failure WARRINGTON, Pa. , June 12, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology

Article Date

This article is featured on another website.

Go to article
No items found.